Bio-Techne (TECH) Short-Term Debt repayments (2014 - 2026)
Bio-Techne (TECH) recorded quarterly Short-Term Debt repayments of $60.0 million in Q1 2026, up 50.0% quarter-over-quarter from $40.0 million in Q4 2025, and up 650.0% on a YoY basis from $8.0 million in Q1 2025.
Bio-Techne (TECH) Short-Term Debt repayments (2014 - 2026) Analysis & Trends
Bio-Techne's Short-Term Debt repayments history runs 13 years deep, the most recent figure standing at $60.0 million for Q1 2026.
- In Q1 2026, Short-Term Debt repayments rose 650.0% year-over-year to $60.0 million; the TTM figure through Mar 2026 stood at $196.0 million (up 102.06% YoY), while the FY2025 annual figure was $77.0 million, down 69.92% from the prior year.
- Short-Term Debt repayments was $60.0 million for Q1 2026 at Bio-Techne, up from $40.0 million in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $441.0 million in Q3 2022 to a low of $3.1 million in Q2 2022.
- Historically, Short-Term Debt repayments has averaged $71.4 million across 5 years, with a median of $58.0 million in 2023.
- Biggest YoY gain for Short-Term Debt repayments was 762.59% in 2022; the steepest drop was 97.6% in 2022.
- A 5-year view of Short-Term Debt repayments shows it stood at $64.7 million in 2022, then dropped by 10.3% to $58.0 million in 2023, then tumbled by 67.24% to $19.0 million in 2024, then jumped by 110.53% to $40.0 million in 2025, then surged by 50.0% to $60.0 million in 2026.
- The last three Short-Term Debt repayments figures came in at $60.0 million (Q1 2026), $40.0 million (Q4 2025), and $46.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 102,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -482,347.21 |
| 10 | Bio-Techne | 8.41 Bn | 8.20 Bn | 208.29 Mn | 60.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.00 Mn |
| Mar 31, 2026 | 60.00 Mn |
| Dec 31, 2025 | 40.00 Mn |
| Dec 31, 2025 | 40.00 Mn |
| Sep 30, 2025 | 46.00 Mn |
| Sep 30, 2025 | 46.00 Mn |
| Jun 30, 2025 | 50.00 Mn |
| Jun 30, 2025 | 50.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Jun 30, 2024 | 70.00 Mn |
| Jun 30, 2024 | 70.00 Mn |
| Mar 31, 2024 | 58.00 Mn |
| Mar 31, 2024 | 58.00 Mn |
| Dec 31, 2023 | 58.00 Mn |
| Dec 31, 2023 | 58.00 Mn |
| Sep 30, 2023 | 70.00 Mn |
| Sep 30, 2023 | 70.00 Mn |